H
Hua Yu
Researcher at Amgen
Publications - 8
Citations - 260
Hua Yu is an academic researcher from Amgen. The author has contributed to research in topics: Neuroblastoma RAS viral oncogene homolog & Panitumumab. The author has an hindex of 4, co-authored 8 publications receiving 232 citations.
Papers
More filters
Journal ArticleDOI
Analysis of KRAS/NRAS Mutations in a Phase III Study of Panitumumab with FOLFIRI Compared with FOLFIRI Alone as Second-line Treatment for Metastatic Colorectal Cancer.
Marc Peeters,Kelly S. Oliner,Timothy J. Price,Andrés Cervantes,Alberto Sobrero,Michel Ducreux,Yevhen Hotko,Thierry André,Emily Chan,Florian Lordick,Cornelis J. A. Punt,Andrew Strickland,Gregory C. Wilson,Tudor Ciuleanu,Laslo Roman,Eric Van Cutsem,Pei He,Hua Yu,Reija Koukakis,Jan Henrik Terwey,A.S. Jung,Roger Sidhu,Scott D. Patterson +22 more
TL;DR: Findings support RAS testing for patients with mCRC and the benefit–risk of panitumumab–FOLFIRI was improved in the wild-type RAS population compared with theWild-type KRAS exon 2 population.
Journal ArticleDOI
Updated analysis of KRAS/NRAS and BRAF mutations in study 20050181 of panitumumab (pmab) plus FOLFIRI for second-line treatment (tx) of metastatic colorectal cancer (mCRC).
Marc Peeters,Kelly S. Oliner,Timothy J. Price,Andrés Cervantes,Alberto Sobrero,Michel Ducreux,Yevhen Hotko,Thierry André,Emily Chan,Florian Lordick,Cornelis J. A. Punt,Andrew Strickland,Gregory C. Wilson,Tudor Ciuleanu,Laslo Roman,Eric Van Cutsem,Hua Yu,A.S. Jung,Roger Sidhu,Scott D. Patterson +19 more
TL;DR: Extended RAS analysis from this study showed a trend toward improvements in HR on OS and PFS with pmab + FOLFIRI vs F OLFIRI in WT RAS group vs WT KRAS exon 2 group.
Journal ArticleDOI
Analysis of KRAS/NRAS mutations in PEAK: A randomized phase II study of FOLFOX6 plus panitumumab (pmab) or bevacizumab (bev) as first-line treatment (tx) for wild-type (WT) KRAS (exon 2) metastatic colorectal cancer (mCRC).
Lee S. Schwartzberg,Fernando Rivera,Meinolf Karthaus,Gianpiero Fasola,Jean-Luc Canon,Hua Yu,Kelly S. Oliner,William Y. Go +7 more
TL;DR: This prospective-retrospective analysis of PEAK showed significantly improved progression free survival (PFS) and overall survival (OS) with pmab + FOLFOX vs FOL FOX in pts with WT RAS (KRAS/NRAS exons 2, 3, 4) mCRC.
Journal ArticleDOI
PEAK (study 20070509): A randomized phase II study of mFOLFOX6 with either panitumumab (pmab) or bevacizumab (bev) as first-line treatment (tx) in patients (pts) with unresectable wild‑type (WT) KRAS metastatic colorectal cancer (mCRC).
Lee S. Schwartzberg,Fernando Rivera,Meinolf Karthaus,Gianpiero Fasola,Jean-Luc Canon,Hua Yu,William Y. Go +6 more
TL;DR: The results of PEAK, a multicenter, randomized phase II study evaluating pmab + mFOLFOX6 and bev + m FOL FOX6 in pts with previously untreated WT KRASmCRC, show significant improvement in progression-free survival and intent-to-treat efficacy.
Journal ArticleDOI
Extended RAS analysis and subsequent anti-EGFR and anti-VEGF treatment (tx) in PEAK: A first-line phase 2 study of FOLFOX6 + panitumumab (pmab) or bevacizumab (bev) in metastatic colorectal cancer (mCRC).
Fernando Rivera,Lee S. Schwartzberg,Meinolf Karthaus,Gianpiero Fasola,Jean-Luc Canon,J. Randolph Hecht,Ying Tian,Hua Yu,Kelly S. Oliner,William Y. Go +9 more
TL;DR: It is shown that progression-free survival was similar and overall survival was improved with pmab + FOLFOX6 relative to bev + F OLFOX6 in patients with WT KRAS exon 2 mCRC in PEAK.